[PDF][PDF] Phase II trial of the anti-CD19 bispecific T cell–engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B …

MS Topp, N Gökbuget, G Zugmaier, P Klappers… - Journal of Clinical …, 2014 - slaop.org
MS Topp, N Gökbuget, G Zugmaier, P Klappers, M Stelljes, S Neumann, A Viardot, R Marks…
Journal of Clinical Oncology, 2014slaop.org
Purpose Patients with relapsed or refractory acute lymphoblastic leukemia (ALL) have a
dismal prognosis. CD19 is homogenously expressed in B-precursor ALL and can be
targeted by the investigational bispecific T cell–engager antibody blinatumomab. A phase II
trial was performed to determine clinical activity in this patient cohort.
Purpose
Patients with relapsed or refractory acute lymphoblastic leukemia (ALL) have a dismal prognosis. CD19 is homogenously expressed in B-precursor ALL and can be targeted by the investigational bispecific T cell–engager antibody blinatumomab. A phase II trial was performed to determine clinical activity in this patient cohort.
slaop.org